Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus TETREX.
ATRIDOX vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic